Astria to present at upcoming Bradykinin Symposium
Astra Therapeutics announced that it will present two posters at the upcoming Bradykinin Symposium in Berlin, Germany on 6 September 2024:
- Chris Morabito, M.D., Chief Medical Officer at Astria Therapeutics, will present information on ALPHA-SOLAR, a long-term open-label trial of navenibart (STAR-0215) in people living with HAE, in an encore presentation of a poster titled “Rationale and Design of the ALPHA-SOLAR Clinical Trial of STAR-0215.”
- Kusumam Joseph, Senior Director of Medical Affairs at Astria Therapeutics, will present results from the Phase 1a trial of navenibart (STAR-0215) in an encore presentation of a poster titled “Phase 1a Trial of STAR-0215 for Hereditary Angioedema: Updated Results.”
Both posters will be presented at the poster session on Friday 6 September at 3:35pm CEST.
(Source: Astria)